However, there is also an increasing number of studies that have questioned the significance of CD133/AC133 as a potential biomarker of GSCs [15–23] or positive predictor of GBM aggressiveness [16, 18, 24, 25]. The gene discussed is PROM1; the disease is glioblastoma.